Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).
Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).
Transfection Reagent for HCT-116 Cells (Colon Carcinoma Cells, CCL-247)
- Proprietary cationic lipids formulation
- High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
- Effective and robust intracellular delivery
- Kit includes Transfection Enhancer reagent
- Produces consistent results, lot-to-lot, plate-to-plate, and well-to-well
- A proven reagent for establishing HCT-116 stable cell lines
- Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
- Download HCT-116 CRISPR/Cas9 transfection protocol: [PDF]
- Download PowerPoint presentation for HCT-116 cells transfection kit: [PPT]
- Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 90% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems HCT116 Transfection Protocol: [PDF]
Download MSDS: [PDF]
HCT-116 Cell Line:
Colon cancer mostly affects older people in their late 60s and early 70s; however, the only group that is associated with increased incidence rates is people younger than age 50, as per the Colon Cancer Alliance (CCA). The HCT-116 colon cancer cell line is essential for researching biochemical pathways that aid the proliferation of colon carcinoma. The HCT-116 cell line was derived from epithelial tumorigenic colon tissue of an adult male with colorectal carcinoma. These cells have a mutation in the 13 codon of the ras proto-oncogene, and therefore they are useful for PCR assays studying this codon. They are also positive for transforming growth factor beta 1 and beta 2 expression. This cell line is useful for biomedical research related to colon cancer. Altogen Biosystems provides highly efficient lipid-based transfection reagent kits for the HCT-116 colon cancer cell line.
Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into HCT-116 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).
Figure 2. Protein expression of Lamin A/C in HCT-116 cells. DNA plasmid expressing Lamin A/C or siRNA targeting Lamin A/C were transfected into HCT-116 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems is a life sciences company that offers cell type-specific and pre-optimized transfection products, electroporation kits, and in vivo delivery reagents. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of protein, DNA, mRNA, shRNA and siRNA molecules. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6811)
- 1.5 ml (Catalog #6812)
- 1.5 ml CRISPR (Catalog #2148)
- 8.0 ml (Catalog #7045)